---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105032"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:44:54.405951+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test

## Summary
- Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.
- Net loss $9.4M ($0.10 per share) vs $17.0M loss a year ago; adjusted net loss $7.5M vs income $0.2M.
- FY2025 guidance: revenue $480-510M (flat to +6%); adjusted EBITDA $31.1-61.9M.
- Fourth Amendment to Credit Agreement waives Q2 2025 covenant test; must reset covenants by Sept 30, 2025; no additional borrowing until then.
- Cash and restricted cash $73.7M, no debt; expects cash plus product sales to fund ops for 12 months.

## SEC filing metadata
- accession: 0000950170-25-105032
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017025105032/0000950170-25-105032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017025105032/orgo-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105032
- JSON: https://secwatch.observer/filing/0000950170-25-105032.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.